Literature DB >> 6697428

Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

M J Yagi, M Zanjani, J F Holland, J G Bekesi.   

Abstract

The cancericidal efficacy of a new synthetic tripeptide was demonstrated using both in vitro cultures and in vivo tumorigenic assays. The antitumor agent PTT.119 (p-F-Phe-m-bis-(2-chloroethyl)amino-Phe-Met ethoxy HCl) was highly effective against three virulent murine tumor models: the L1210 leukemia, MJY-alpha mammary tumor and B16 melanoma. Treatment of tumor cells for periods as short as 15 min to 4 h with concentrations of 1-50 micrograms PTT.119/ml irreversibly reduced tumor cell viability, as evidenced by vital dye exclusion and abrogation of tumor formation and prolongation of host survival. Examination of the sensitivity of mice to PTT.119 revealed that the in vitro antitumor activity of the synthetic tripeptide was exerted at concentrations easily attainable and well tolerated in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6697428     DOI: 10.1007/bf00254593

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  The use of body surface area as a criterion of drug dosage in cancer chemotherapy.

Authors:  D PINKEL
Journal:  Cancer Res       Date:  1958-08       Impact factor: 12.701

2.  Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links.

Authors:  W E Ross; R A Ewig; K W Kohn
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

3.  Factors determining cell killing by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil and nitrogen mustard.

Authors:  L M van Putten; P Lelieveld
Journal:  Eur J Cancer       Date:  1971-02       Impact factor: 9.162

4.  Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro.

Authors:  G J Goldenberg; M Lee; H Y Lam; A Begleiter
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

5.  Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents.

Authors:  J E Byfield; P M Calabro-Jones
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

Review 6.  L-phenylalanine mustard (L-PAM): the first 25 years.

Authors:  R L Furner; R K Brown
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

7.  Antitumor drug toxicity in tumor-free and tumor-bearing mice.

Authors:  S D Harrison; H D Giles; E P Denine
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

Authors:  M J Yagi; J G Bekesi; M D Daniel; J F Holland; A De Barbieri
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  Mechanism of melphalan resistance developed in vitro in human melanoma cells.

Authors:  P G Parsons; F B Carter; L Morrison
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

10.  L-phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line.

Authors:  L W Brox; B Gowans; A Belch
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

View more
  7 in total

1.  Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas.

Authors:  F Gherlinzoni; P Mazza; P L Zinzani; S Tura; F Lanza; G Castoldi; G Bellesi; P L Rossi Ferrini; L Mangoni; V Rizzoli
Journal:  Blut       Date:  1990-03

2.  Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma.

Authors:  G Visani; R M Lemoli; P Tosi; F Verlicchi; B Gamberi; A R Cenacchi; R Colombini; M Fogli; D Russo; E Zuffa
Journal:  Blut       Date:  1990-05

3.  Phase I study of beta-alanyl-melphalan as a potent anticancer drug.

Authors:  B L Tsay; L Wolfinbarger
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas.

Authors:  S Tura; P Mazza; F Gherlinzoni; P L Zinzani; G Poletti; G Visani; R M Lemoli; M Cavo; P Galieni; C Tassi
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119).

Authors:  F Verlicchi; S Boschi; G Visani; A Guidi; P Tosi; M Cavo; S Tura
Journal:  Blut       Date:  1990-11

6.  Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia.

Authors:  M J Yagi; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Evaluation of 3-(p-fluorophenyl)-L-alanyl-3-[m-bis-(2-chloroethyl) aminophenyl]-L-alanyl-L-methionine ethyl ester HCl (PTT.119) against xenografts of human rhabdomyosarcoma.

Authors:  P J Houghton; R Tharp; J A Houghton; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.